- Company
- Reimbursement listing of Handok’s Doptelet near
- by Son, Hyung Min Apr 11, 2025 06:00am
- Doptelet, Handok’s newly introduced drug, is close to being listed for insurance reimbursement in Korea. According to industry sources, Handok has accepted the conditions presented by the Drug Reimbursement Evaluation Committee of the Health Insurance Review and Assessment Service for Doptelet (avatrombopag), a treatment for immune throm
- Company
- Biosimilars to Prolia compete for the market worth KRW 170B
- by Whang, byung-woo Apr 10, 2025 05:57am
- As biosimilars have been introduced following the patent expiration of the osteoporosis treatment, 'Prolia (denosumab),' competition in the market is expected to heat up. As biosimilars from Celltrion and Samsung Bioepis, distributed by Daewoong and Hanmi, respectively, become distributed, the original drug producer, Chong Kun Dang, and the b
- Company
- Yuhan "Immunotherapy candidate, Phase 1/2 IND approved"
- by Kim, Jin-Gu Apr 10, 2025 05:57am
- Yuhan announced on April 7 that it received approval from the Ministry of Food and Drug Safety (MFDS) for its investigational new drug (IND) application to initiate Phase ½ trial of 'YH32364,' a novel immunotherapy for cancer under development. According to Yuhan, YH32364 is a bispecific antibody that simultaneously targets epidermal gro
- Company
- Dupixent aims to meet unmet needs in COPD
- by Whang, byung-woo Apr 10, 2025 05:56am
- Dupixent (dupilumab), which is leading the atopic dermatitis market, is seeking to enter the market as Korea's first chronic obstructive pulmonary disease (COPD) targeted biologic drug. The company wants to open a new paradigm in the treatment of COPD, which has a high unmet need, based on Dupixent’s mechanism that targets interleukin (IL)-4
- Company
- Novartis, PNH drug 'Fabhalta' enters drug pricing nego.
- by Eo, Yun-Ho Apr 10, 2025 05:56am
- The new oral drug 'Fabhalta' has entered the last phase of receiving approval for insurance reimbursement. According to industry sources, Novartis Korea’s ’Fabhalta (iptacopan),’ a treatment for paroxysmal nocturnal hemoglobinuria (PNH), is under negotiations for drug pricing. Consequently, attention is gaining to whether another tr
- Company
- Will Leqvio not be reimbursed for ASCVD in Korea?
- by Eo, Yun-Ho Apr 9, 2025 05:56am
- The reimbursement of the twice-yearly dyslipidemia drug ‘Leqvio’ for ASCVD became unclear in Korea. According to Dailpharm coverage, the siRNA drug, Leqvio (inclisiran), from Novartis Korea failed to set reimbursement standards at the Drug Reimbursement Evaluation Subcommittee meeting of the Health Insurance Review and Assessment Servic
- Company
- Doctors long for a new treatment option for liver cancer
- by Moon, sung-ho Apr 9, 2025 05:56am
- Progressive hepatocellular carcinoma, or liver cancer, is a disease with only a few effective treatment options in the clinical setting. Recently, the emergence of various first-line treatment options such as targeted anticancer drugs and immuno-oncology drugs, has raised expectations for improved treatment outcomes. However, treatment option
- Company
- Trials for bispecific antibodies in cancer immunotherapy
- by Son, Hyung Min Apr 9, 2025 05:56am
- Yuhan, Hanmi Pharmaceuticals, and other domestic pharmaceutical and biotech companies have entered Phase 1 clinical trials of bispecific immuno-oncology drugs, delving into new drug development. Bispecific antibodies are drugs that can simultaneously bind to two different antigens or two distinct antigen-binding sites on the same antigen. Mul
- Company
- Samsung Bioepis launches Epysqli in the US
- by Whang, byung-woo Apr 9, 2025 05:56am
- Samsung Bioepis (CEO Kyung-ah Kim) announced on the 8th that it has launched Epysqli (project name SB12, ingredient name eculizumab), a treatment for rare diseases, in the US through its marketing partner, Teva. Epysqli is a biosimilar version of Soliris. Soliris is a treatment for rare diseases such as paroxysmal nocturnal hemoglobinuria
- Company
- ABL licenses out its tech to big pharmas worth ₩350B
- by Cha, Jihyun Apr 8, 2025 05:57am
- ABL Bio has signed a licensing-out agreement worth KRW 70 billion in advance payments (upfront). This is the company's 7th licensing-out agreement and its first platform deal. Including this contract, the cumulative technology fee ABL Bio earned through technology exports is close to KRW 350 billion. According to the Financial Supervisory
